Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from Guggenheim

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a report released on Friday,Benzinga reports. They presently have a $60.00 price target on the stock. Guggenheim’s price target would suggest a potential upside of 81.76% from the company’s current price.

A number of other analysts have also recently commented on the stock. Piper Sandler initiated coverage on shares of Oruka Therapeutics in a research report on Thursday, December 18th. They set an “overweight” rating and a $75.00 price target on the stock. Wedbush lifted their target price on Oruka Therapeutics from $42.00 to $45.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. BTIG Research lifted their price target on Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 8th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $54.50.

Oruka Therapeutics Price Performance

ORKA opened at $33.01 on Friday. The stock has a market capitalization of $1.60 billion, a P/E ratio of -17.37 and a beta of -0.38. The business has a 50 day simple moving average of $32.68 and a 200-day simple moving average of $27.32. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $36.53.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. Research analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current year.

Insider Buying and Selling at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the transaction, the insider directly owned 34,018 shares in the company, valued at $1,101,162.66. This trade represents a 17.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 21,000 shares of company stock worth $663,530. Corporate insiders own 24.69% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its position in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the period. Kennedy Capital Management LLC grew its stake in Oruka Therapeutics by 0.9% during the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after buying an additional 420 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after buying an additional 788 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Oruka Therapeutics by 62.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after buying an additional 904 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics in the 4th quarter valued at $37,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.